Cerus Corp Files 8-K Report
Ticker: CERS · Form: 8-K · Filed: Mar 19, 2024 · CIK: 1020214
| Field | Detail |
|---|---|
| Company | Cerus Corp (CERS) |
| Form Type | 8-K |
| Filed Date | Mar 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, routine-report
TL;DR
Cerus Corp filed a routine 8-K, no major news.
AI Summary
On March 19, 2024, Cerus Corporation filed an 8-K report to disclose other events and financial statements. The filing does not contain specific details on new material events, acquisitions, or significant financial changes beyond routine reporting requirements.
Why It Matters
This filing serves as a routine update for investors and the public, confirming Cerus Corporation's adherence to SEC reporting requirements.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not indicate any new material risks or significant changes in the company's operations.
Key Players & Entities
- CERUS CORP (company) — Registrant
- 000-21937 (company) — SEC File Number
- 68-0262011 (company) — IRS Employer Identification No.
- 1220 Concord Avenue, Suite 600 (company) — Principal Executive Offices Address
- Concord, California (company) — Principal Executive Offices Location
- 94520 (company) — Principal Executive Offices Zip Code
- 925 288-6000 (company) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for Cerus Corporation?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of March 19, 2024.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is March 19, 2024.
What is Cerus Corporation's state of incorporation?
Cerus Corporation's state of incorporation is Delaware.
What is the business address of Cerus Corporation?
The business address of Cerus Corporation is 1220 Concord Avenue, Suite 600, Concord, California, 94520.
Does this filing indicate any significant new developments or financial changes for Cerus Corporation?
Based on the provided text, this filing is a standard 8-K report for 'Other Events' and 'Financial Statements and Exhibits' and does not detail specific new material developments or financial changes.
Filing Stats: 465 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-03-19 08:02:31
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CERS The Nasdaq Stock Mar
Filing Documents
- cers-20240319.htm (8-K) — 36KB
- cers-ex99_1.htm (EX-99.1) — 25KB
- 0000950170-24-033155.txt ( ) — 176KB
- cers-20240319.xsd (EX-101.SCH) — 23KB
- cers-20240319_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On March 19, 2024, Cerus Corporation (the "Company") issued a press release announcing positive topline results of its U.S. Phase 3 clinical trial of the INTERCEPT Blood System for Red Blood Cells in cardiovascular surgery patients. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 99.1 Press release, dated March 19, 2024, entitled "Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients." 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CERUS CORPORATION Date: March 19, 2024 By: /s/ Chrystal N. Jensen Chief Legal Officer and General Counsel